Daiichi Sankyo Company, Limited Overview
Pro stress-test →Daiichi Sankyo is a global pharmaceutical company and the second-largest pharmaceutical company in Japan. The company is strategically focused on oncology, with a strong portfolio in antibody-drug conjugates (ADCs), particularly its proprietary DXd platform used in flagship drugs like ENHERTU and DATROWAY developed in partnership with AstraZeneca.
Strategic Profile
Pro stress-test →Daiichi Sankyo's ADC portfolio consists of eight ADCs in clinical development, with seven ADCs in the DXd technology platform where ENHERTU and DATROWAY are jointly developed with AstraZeneca, and other candidates jointly developed with Merck & Co. The company has strategically pivoted away from diversified pharmaceutical portfolios to concentrate on oncology innovation and next-generation cancer therapeutics.
Competitive Landscape
Pro stress-test →Daiichi Sankyo competes in the oncology pharmaceutical market against major global companies including Roche, Novartis, and Merck, as well as emerging biotech firms focused on ADC technology. The company's differentiated DXd platform and strategic partnerships with AstraZeneca position it as a significant player in targeted cancer therapeutics, competing particularly in HER2-positive and triple-negative breast cancer, and expanding into hematologic malignancies.
Industry Context
Daiichi Sankyo Company, Limited operates in Pharmaceuticals & Biotechnology - Oncology.
Key facts
Founded: 2005 · Headquarters: Tokyo, Japan · Revenue: JPY 1.278 trillion